- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Trial at the Charing Cross 31st International Symposium in London
Nicast plans to begin post marketing clinical studies in Europe in 2009
Nicast, developer of medical devices made of electrospun nanofabric, announced today that it will exhibit the AVflo™ vascular access graft for hemodialysis, its flagship product which received CE certification in October 2008, at the Charing Cross 31st International Symposium in London, April 4-7, 2009, booth number 154.
During the conference, Professor S Mandika Wijeyaratne, MBBS MS MD (Leeds) FRCS(Eng), Professor in Surgery, University of Colombo, Consultant Vascular & Transplant Surgeon, National Hospital Colombo, Sri Lanka and the PI of the AVFlo clinical study, will address participants on the topic "Safety and efficacy of a new polycarbonate-urethane graft for early vascular access in end stage renal disease: First clinical results in man". The presentation will take place on Sunday, April 5th at 16:50 at the CX "New Technology Dragon's Den" Learning Center 3. Professor Wijeyaratne will also be available during the conference at Nicast's booth to answer any questions.
AVflo is a self-sealing vascular access graft that enables unobstructed blood flow, allows for dialysis within 24-48 hours after implantation and self-seals within less than five minutes following withdrawal of the dialysis needles. It is simple to implant and to suture to blood vessels; the needle punctures and suture holes self-seal rapidly. AVflo is also strong enough to withstand the pressure of blood flow, yet thin enough for blood flow to be easily felt through it.
"This is an exciting time for Nicast as we are transitioning from a pre-sales company to a revenue generating company. We already have sales of AVflo in Europe and South East Asia, and we are expanding our network of select distributors in key countries. Nicast is also planning to commence in the near future a post marketing multi-site clinical study of AVflo in Europe," said Mr. Benjamin Eliason, CEO of Nicast.
"The medical community has been quite impressed with Nicast's electrospinning technology and products. We are enjoying an unprecedented level of interest in pursuing joint projects, a topic we are always open to discussing," said Dr. Jacob Dagan, chairman of the board of Nicast.
Details of the studies will be released in a future communication.
About Nicast Ltd.
Nicast Ltd. is a pioneer in the development of superior implantable medical devices made of electrospun polymer nanofabrics for a wide range of applications. The company is currently focused on the development and marketing of the AVflo vascular access graft and the NovaMesh ventral hernia mesh, which address a combined global market of $0.7 billion to $1 billion. Headquartered in Lod, Israel, Nicast has six patents in the U.S., ten patents outside of the U.S. and 14 additional patents pending.
For more information, please click here
Copyright © Nicast Ltd.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016
Nanosciences: Genes on the rack October 21st, 2016
Nanoparticle vaccinates mice against dengue fever October 21st, 2016
Leti Scientists Participating in Sessions on Med Tech, Automotive Technologies, MEMS, Si-photonics and Lithography at SEMICON Europa: Teams also Will Demonstrate Technology Advances in Telecom, Data Fusion, Energy, Silicon Photonics and 3D Integration October 18th, 2016